Average Co-Inventor Count = 4.98
ph-index = 20
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Theravance, Inc. (90 from 386 patents)
2. Theravance Biopharma R&d Ip, LLC (40 from 262 patents)
3. Syntex (u.s.a.) Inc. (5 from 932 patents)
4. Dice Alpha, Inc. (3 from 3 patents)
5. Advanced Medicine, Inc. (2 from 13 patents)
6. Axys Pharmaceuticals, Inc. (1 from 40 patents)
7. An2h Discovery Limited (1 from 2 patents)
8. Nysnobio Ireland Dac (1 from 1 patent)
143 patents:
1. 12358931 - 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
2. 12234225 - IL-17 ligands and uses thereof
3. 11878977 - JAK inhibitors containing a 4-membered heterocyclic amide
4. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease
5. 11667637 - Fused imidazo-piperidine JAK inhibitors
6. 11453668 - JAK inhibitors containing a 4-membered heterocyclic amide
7. 11447468 - IL-17 ligands and uses thereof
8. 11299492 - JAK kinase inhibitor compounds for treatment of respiratory disease
9. 11274094 - Substituted benzenecarboxamides as IL-17A modulators
10. 11254669 - Fused imidazo-piperidine JAK inhibitors
11. 11160810 - Fused imidazo-piperidine JAK inhibitor compound
12. 11110095 - Pyrimidine compounds as JAK kinase inhibitors
13. 10968222 - 2-azabicyclo hexane JAK inhibitor compound
14. 10954237 - JAK inhibitors containing a 4-membered heterocyclic amide
15. 10913740 - JAK kinase inhibitor compounds for treatment of respiratory disease